Saving the "brain rainforest" in Alzheimer's disease: from single-node protection to ecosystem restoration

The high failure rate of Alzheimer's disease (AD) drugs highlights the limitation of traditional single-target therapies for a disease with a heterogenous pathology. A recent study published in Cell by Li et al. pioneers a paradigm shift towards cell-type-directed combination therapy. By integrating snRNA-seq and real-world data, they repurposed letrozole and irinotecan and demonstrated that this combination effectively reverses multifaceted AD pathologies in mice.